Ulrike Lorch

List of Publications by Year
in descending order

36	846	516215 16	500791 28
papers	citations	h-index	g-index

36	36	36	1194
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Safety, Tolerability, and Dose Proportionality of a Novel Transdermal Fentanyl Matrix Patch and Bioequivalence With a Matrix Fentanyl Patch: Two Phase 1 Singleâ€Center Openâ€Label, Randomized Crossover Studies in Healthy Japanese Volunteers. Clinical Pharmacology in Drug Development, 2021, 10, 260-271.	0.8	0
2	Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study. European Heart Journal, 2021, 42, 178-188.	1.0	190
3	Confirmation of the cardiac safety of nolasiban in a randomised cohort of healthy female volunteers. Scientific Reports, 2021, 11, 6404.	1.6	0
4	Phase 1/2 Study of Lumasiran for Treatment of Primary Hyperoxaluria Type 1. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1025-1036.	2.2	48
5	Concentrationâ€QT modelling of the novel DHFR inhibitor P218 in healthy male volunteers. British Journal of Clinical Pharmacology, 2021, , .	1.1	2
6	The mechanism of action of oxytocin antagonist nolasiban in ART in healthy female volunteers. Reproductive BioMedicine Online, 2021, 43, 184-192.	1.1	3
7	Kinetics of anti-SARS-CoV-2 IgG antibody levels and potential influential factors in subjects with COVID-19: A 11-month follow-up study. Diagnostic Microbiology and Infectious Disease, 2021, 101, 115537.	0.8	8
8	Efficient Design of Integrated and Adaptively Interlinked Protocols for Early-Phase Drug Development Programs. Therapeutic Innovation and Regulatory Science, 2020, 54, 184-194.	0.8	0
9	Safety, Tolerability, Pharmacokinetics, and Antimalarial Activity of the Novel Plasmodium Phosphatidylinositol 4-Kinase Inhibitor MMV390048 in Healthy Volunteers. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	39
10	Firstâ€inâ€human clinical trial to assess the safety, tolerability and pharmacokinetics of P218, a novel candidate for malaria chemoprotection. British Journal of Clinical Pharmacology, 2020, 86, 1113-1124.	1.1	33
11	Time- and Race-Specific Haematological Reference Intervals for Healthy Volunteer Trials: A Retrospective Analysis of Pooled Data From Multiple Phase I Trials. Frontiers in Pharmacology, 2020, 11, 314.	1.6	24
12	Pharmacokinetics of Tramadol and Celecoxib in Japanese and Caucasian Subjects Following Administration of Co-Crystal of Tramadol-Celecoxib (CTC): A Randomised, Open-Label Study. European Journal of Drug Metabolism and Pharmacokinetics, 2019, 44, 63-75.	0.6	6
13	Efficient Design of Integrated and Adaptively Interlinked Protocols for Early-Phase Drug Development Programs. Therapeutic Innovation and Regulatory Science, 2019, , 216847901882108.	0.8	0
14	Coadministration of the prostaglandin F2Îµ receptor antagonist preterm labour drug candidate OBE022 with magnesium sulfate, atosiban, nifedipine and betamethasone. British Journal of Clinical Pharmacology, 2019, 85, 1516-1527.	1.1	6
15	Practical risk management in early phase clinical trials. European Journal of Clinical Pharmacology, 2019, 75, 483-496.	0.8	9
16	Pharmacokinetics, safety and tolerability of OBE022, a selective prostaglandin F2Îµ receptor antagonist tocolytic: A firstâ€inâ€human trial in healthy postmenopausal women. British Journal of Clinical Pharmacology, 2018, 84, 1839-1855.	1.1	13
17	Confirmation of the Cardiac Safety of PGF_{2Îµ} Receptor Antagonist OBE022 in a Firstâ€inâ€Human Study in Healthy Subjects, Using Intensive ECG Assessments. Clinical Pharmacology in Drug Development, 2018, 7, 889-900.	0.8	12
18	Pharmacokinetics of concentrated naloxone nasal spray for opioid overdose reversal: Phase I healthy volunteer study. Addiction, 2018, 113, 484-493.	1.7	65

#	Article	IF	Citations
19	A firstâ€inâ€man safety and pharmacokinetics study of nangibotide, a new modulator of innate immune response through TREMâ€1 receptor inhibition. British Journal of Clinical Pharmacology, 2018, 84, 2270-2279.	1.1	27
20	Pharmacokinetics and Safety of the Oral Prostaglandin F2alpha Receptor Antagonist OBE022: A First-In-Human Study in Healthy Post-Menopausal Women. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO1-11-7.	0.0	0
21	The pharmacokinetic interaction of the selective PGF2Î± receptor antagonist OBE022 on co-administration with MgSO₄, atosiban, nifedipine or betamethasone. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, OR22-4.	0.0	0
22	Diurnal and racial variance of white blood cell parameters in early phase clinical trials: a retrospective analysis of pooled data from multiple phase I trials. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, OR25-1.	0.0	0
23	Pharmacokinetics and pharmacogenetics of the MEK1/2 inhibitor, selumetinib, in Asian and Western healthy subjects: a pooled analysis. European Journal of Clinical Pharmacology, 2017, 73, 717-726.	0.8	10
24	Thorough QT study of the effect of intravenous amisulpride on QTc interval in Caucasian and Japanese healthy subjects. British Journal of Clinical Pharmacology, 2017, 83, 339-348.	1.1	35
25	Pharmacokinetics, Safety and Cognitive Function Profile of Rupatadine 10, 20 and 40 mg in Healthy Japanese Subjects: A Randomised Placebo-Controlled Trial. PLoS ONE, 2016, 11, e0163020.	1.1	10
26	Single Doses up to 800 mg of E-52862 Do Not Prolong the QTc Interval â€“ A Retrospective Validation by Pharmacokinetic-Pharmacodynamic Modelling of Electrocardiography Data Utilising the Effects of a Meal on QTc to Demonstrate ECG Assay Sensitivity. PLoS ONE, 2015, 10, e0136369.	1.1	14
27	The Power of Phase I Studies to Detect Clinical Relevant QTc Prolongation: A Resampling Simulation Study. BioMed Research International, 2015, 2015, 1-8.	0.9	20
28	Thorough <scp>QT</scp> study of the effect of oral moxifloxacin on <scp>QT_c</scp> interval in the fed and fasted state in healthy <scp>J</scp>apanese and <scp>C</scp>aucasian subjects. British Journal of Clinical Pharmacology, 2014, 77, 170-179.	1.1	44
29	Analyzing the relationship of QT interval and exposure toNitazoxanide, a prospective candidate for influenza antiviral therapy-A formal TQT study. Journal of Clinical Pharmacology, 2014, 54, 987-994.	1.0	7
30	Three steps to writing adaptive study protocols in the early phase clinical development of new medicines. BMC Medical Research Methodology, 2014, 14, 84.	1.4	19
31	Insulin at normal physiological levels does not prolong QTcinterval in thorough QT studies performed in healthy volunteers. British Journal of Clinical Pharmacology, 2013, 75, 392-403.	1.1	22
32	Bupivacaine Extended Release Liposome Injection Does Not Prolong QTc Interval in a Thorough QT/QTc Study in Healthy Volunteers. Journal of Clinical Pharmacology, 2012, 52, 1441-1447.	1.0	35
33	Repeated supratherapeutic dosing of strontium ranelate over 15â€ƒdays does not prolong QTc interval in healthy volunteers. British Journal of Clinical Pharmacology, 2012, 74, 296-303.	1.1	4
34	Levofloxacin can be used effectively as a positive control in thorough QT/QTc studies in healthy volunteers. British Journal of Clinical Pharmacology, 2010, 69, 391-400.	1.1	31
35	Similar Rivastigmine Pharmacokinetics and Pharmacodynamics in Japanese and White Healthy Participants Following the Application of Novel Rivastigmine Patch. Journal of Clinical Pharmacology, 2009, 49, 430-443.	1.0	18
36	Lamotrigine does not prolong QTc in a thorough QT/QTc study in healthy subjects. British Journal of Clinical Pharmacology, 2008, 66, 396-404.	1.1	92